By Douglas Clarke-Williams ( June 16, 2026, 14:13 GMT | Insight) -- Accord has begun efforts in the English courts to invalidate Novartis’s patent for blood pressure medicine ahead of an anticipated launch of its own generic medication. Over a week-long trial, Accord is hoping to show that the patent didn’t show the proper data, was obvious over prior art, and made no technical contribution to that prior art.Accord Healthcare, a subsidiary of Indian company Intas Pharmaceuticals, is challenging Swiss healthcare multinational Novartis over the underlying patent for Entresto, a medication for treating heart failure....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.